students on campus



Profile for C. Patrick Reynolds, MD, PhD

C. Patrick Reynolds

C. Patrick Reynolds, MD, PhD

  • Covenant Health Systems David R. Close, MD Endowed Chair in Oncology
  • Cancer Center Director (Tenured)
  • Distinguished University Professor (with tenure) (Tenured), Department of Pediatrics
  • Director of the South Plains Oncology Consortium (www.SPONC.org)
  • Director, ALSF and COG Childhood Cancer Repository
Mail Address: 3601 4th St Stop 9445
Lubbock TX 79430-9445

Biography

Dr. Reynolds grew up in El Paso, TX, received his BA in Biology from The University of Texas at Austin, his MD from UT Southwestern Medical School in Dallas, TX, his PhD (Cell Biology) from UT Austin, and his pediatrics training at the National Naval Medical Center. His postdoctoral fellowship was in cancer immunology at UT Southwestern Medical School, Dallas, TX. He is currently the Cancer Center Director for the School of Medicine, Texas Tech University Health Sciences Center (http://cancer.ttuhsc.edu), and is Director of the South Plains Oncology Consortium (SPOC; www.SPONC.org).

Dr Reynolds’ research focuses on retinoids (drugs derived from vitamin A) in treating cancer, and he pioneered the development of the differentiating agent isotretinoin for treating the childhood cancer neuroblastoma, which is now world-wide standard of care. His phase III clinical trial design that demonstrated effectiveness of treating minimal residual disease after myeloablative therapy with isoretinoin has led to other successful phase III neuroblastoma studies, most recently adding anti-GD2 antibody and cytokines to isotretinoin to significantly improve survival in high-risk neuroblastoma. He discovered that neuroblastoma cells resistant to retinoic acid were highly sensitive to the cytotoxic retinoid fenretinide and he identified key mechanisms of action for fenretinide that have led to mechanistic-based drug combination clinical trials. He developed novel formulations that have enabled single agent fenretinide to achieve complete responses in early phase clinical trials of neuroblastoma and adult lymphomas, paving the way for planned phase II and III studies. Other research interests include mechanisms of drug resistance and drugs to modulate resistance in childhood and adult cancers, development of novel preclinical testing models and systems for cancer drug development, and clinical trials testing novel therapeutic approaches for cancer, especially neuroblastoma, lymphomas, and ovarian cancer.

Dr. Reynolds is a member of the steering committee for neuroblastoma of the Children's Oncology Group (COG). He is a special government employee with the FDA and a founding member of the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee for the FDA. He is a member of the Advisory Committee on Childhood Cancer for the Cancer Prevention and Research Institute of Texas. He is a member of the Best Pharmaceuticals for Children Act prioritization panel for the National Institute for Child Health and Development. Honors received include the 2004 Eurand Prize, 2008 Advances in Neuroblastoma Research Best Clinical Paper, the most cited paper in Clinical Cancer Research in 2009, the Texas Tech University System 2011 Chancellor's Council Distinguished Research Award, The Covenant Health Systems David R. Close, MD Endowed Chair in Oncology, and Distinguished University Professor.

Dr. Reynolds sponsors multiple FDA Investigational New Drug (IND) applications and has active grant support from the National Cancer Institute (NCI),the Cancer Prevention & Research Institute of Texas (CPRIT), and the Department of Defense. The ALSF/COG Childhood Cancer Repository (www.CCCells.org) is a Children’s Oncology Group (COG) national resource laboratory under his direction at Texas Tech. Dr. Reynolds is an author or co-author of more than 200 peer-reviewed scientific papers (H Index = 74) and is a member of editorial boards for Clinical Cancer Research and Molecular Cancer Therapeutics. His avocations include film making and special effects, playing guitar, and writing music. He also enjoys competitive shooting and he was the team physician for the 1992 USA Olympic shooting team in Barcelona.

Positions:

  • Cancer Center Director (Tenured), Texas Tech University Health Sciences Center Lubbock, TX 2008-Present
  • Distinguished University Professor (with tenure) (Tenured), Department of Pediatrics, School of Medicine, Texas Tech University Health Sciences Center Lubbock TX 2008-Present
  • Director of the South Plains Oncology Consortium (www.SPONC.org), Texas Tech University Health Sciences Center Lubbock, TX 2008-Present
  • Director, ALSF and COG Childhood Cancer Repository, Children's Oncology Group Lubbock, TX 2005-Present

Post Doctoral Education:

  • Residency: National Naval Medical Center, 1981
  • Postdoctoral Fellow: University of Texas, Southwestern Medical School, 1980

Education:

  • MD: University of Texas, Southwestern Medical School, 1979
  • PhD: University of Texas at Austin, 1979
  • BA: University of Texas at Austin, 1974
  • High School Diploma: Ysleta High School, 1970

Summary of Scholarly Activity:

    2018-08-01

    I pioneered the development of the differentiating agent isotretinoin for treating the childhood cancer neuroblastoma, and developed clinical trials that established the world-wide standard of care for neuroblastoma. Together with Dr. Maurer we identified key mechanisms of action for cytotoxic retinoid fenretinide that have led to mechanistic-based drug combination clinical trials. We developed novel formulations that have enabled single agent fenretinide to achieve complete responses in early phase clinical trials of neuroblastoma and adult lymphomas.. I have established the largest collection of pediatric cancer cell lines and xenografts in the world and provide these laboratory models of childhood cancer freely to investigators in 20 different countries. A major focus of my lab currently is the study of telomere lengthening mechanisms as biomarkers and therapeutic targets for cancer.


Selected Publications:

  • Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith MP, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.. Frontiers in immunology 2018;9:1355.
  • Lochmann TL, Powell KM, Ham J, Floros KV, Heisey DAR , Kurupi RIJ , Calbert ML, Ghotra MS, Greninger P, Dozmorov M, Gowda M, Souers AJ, Reynolds CP, Benes CH, Faber AC. Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.. Science translational medicine 2018;10(441).
  • Mohrbacher AM, Yang AS, Groshen S, Kummar S, Gutierrez ME, Kang MH, Tsao-Wei D, Reynolds CP, Newman EM, Maurer BJ. Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial.. Clin. Cancer Res. 2017;23(16):4550-4555.
  • Dagg RA, Pickett HA, Neumann AA, Napier CE, Henson JD, Teber ET, Arthur JW, Reynolds CP, Murray J, Haber M, Sobinoff AP, Lau LM, Reddel RR. Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres.. Cell Rep 2017;19(12):2544-2556.
  • Chen NE, Maldonado N, Khankaldyyan V, Shimada H, Song MM, Maurer BJ, Reynolds CP. Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts.. Mol. Cancer Ther. 2016;15(11):2653-2664.
  • Kang MH, Wang J, Makena M, Lee J, Paz N, Song M, Calderon R, Cruz R, Hindle A, Ko W, Fitzgerald J, Drummond D, Hall C, Triche T, Reynolds CP. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewings family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.. Clinical Cancer Research 2015;21:1139-1150.
  • Sheard M, Ghent M, Kang MH, Carbral D, Lee J, Khankaldyyan V, Ji L, Wu S, Sposto R, Asgharzadeh S, Reynolds CP. The Warbug effect is preserved by establishing new childhood acute lymphoblastic leukemia cell lines in physiologic oxygen tension.. Experimental Cell Research 2015;334:78-89.
  • Tagde A, Singh H, Kang MH, Reynolds C. Glutathione synthesis inhibitor buthionine sulfoximine synergized melphalan activity against preclinical models of multiple myeloma. Blood Cancer Journal 2014;18.
  • Kang MH, Smith MA, Morton CL, Nino Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model description for in vitro cytotoxicity testing.. Pediatr Blood Cancer 2011;56:239-49.
  • Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger RC, Reynolds CP. Anti-GD2 antibody with GM-CSF, IL2 and isotretinoin for neuroblastoma: A Children’s Oncology Group (COG) Phase III Study.. New England J Medicine 2010;363:22-32.
  • Kang MH, , Reynolds CP. Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancertherapy.. Clinical Cancer Research 2009;15:1126-1132.
  • Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shamada H, Black CG, Brodeur GM, Gerbing R, Reynolds CP. Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid.. New England J Medicine 1999;341:1165-1173.
  • Thiele CJ, , Reynolds CP, Israel MA . Decreased expression of N-myc precedes retinoic acid induced morphological differentiation of human neuroblastoma.. Nature 1985;313:404-407.

Selected Presentations:

  • Reynolds CP., South Korea Lymphoma Clinical Investigators Meeting, Seoul, South Korea June 2016.
    Phase II study of intravenous fenretinide in peripheral T cell lymphoma.
  • Reynolds CP., Littlefield Primary School , March 2014.
    Cancer Research and Fundraising
  • Jenkins MR, Woodburn T, Knight A, Day L, Ronaghan C, Rahman R, Arentz Ary SC, Cordero J, Quick D, Tafur I, Graham S, Pinto J, Wachtel M, Miller B, Arredondo M, Nahleh Z, Lea J, Gazdar A, Reynolds CP., South Plains Oncology Consortium Cancer Biobank, CPRIT, Austin, Texas November 2011.
  • Reynolds CP., Charleston Ceramide Conference, Dinner, Asilomar Conf Center March 2007.
    Musical Performances with The Flipside (Guitar and Vocals) Charleston Ceramide Conference, Dinner, Asilomar Conf Center
  • Reynolds CP., Advances in Neuroblastoma Research Meeting Reception, Universal City, Los Angeles, May 18, 2006, Universal City, Los Angeles, CA 2006.
    Musical Performance with The Flipside (Guitar and Vocals)Advances in Neuroblastoma Research Meeting Reception, Universal City, Los Angeles, May 18, 2006
  • Reynolds CP., Childrens Oncology Group 50th Anniversary Gala, Reception, Los Angeles, Oct 6, 2006, Los Angeles, CA 2006.
    Musical Performances with The Flipside (Guitar and Vocals)Chldrens Oncology Group 50th Anniversary Gala, Reception, Los Angeles, Oct 6, 2006
  • Reynolds CP., New Approachs to Neuroblastoma Therapy Reception and Dinner, Redondo Beach Feb 2006, Redondo Beach, CA Feb 2006 2006.
    Musical Performance with The Flipside (Guitar and Vocals)
  • Reynolds CP., NBLASTOMA email listserv, Internet 2004.
    Internet Presentation: From 1998 to 2004, posting of teaching communication for parents in the NBLASTOMA email listserv, including responses to questions by parents on the list. An average of 1 to 2 posts per month.

Selected Contracts and Grants:

  • Alex's Lemonade Stand Foundation
    2018-2023
    COG/ALSF Childhood Cancer Repository
    $1,158,330.00 [Total Cost]
    Principal Investigator
  • National Cancer Institute, R01
    2018-2023
    Alternate telomere maintenance mechanisms in high-risk neuroblastoma as prognostic indicators and therapeutic targets
    $1,999,940.00 [Total Cost]
    Principal Investigator
  • Cancer Prevention & Research Institute of Texas (CPRIT), RP170510
    2016-2020
    Telomere Maintenance Mechanisms in Neuroblastoma
    $1,100,000.00 [Total Cost]
    Principal Investigator
  • NCI, RO1 CA221957
    2017-2020
    Characterization of a panel of neuroblastoma patient-derived models for preclinical therapeutic studies
    $1,622,266.00 [Total Cost]
    Co-Principal Investigator
  • Cancer Prevention and Research Institute of Texas (CPRIT), RP170470
    2016-2020
    OCT4/c-MYC axis as a mechanism of resistance to 13-cis retinoic acid in neuroblastoma
    $1,115,137.00 [Total Cost]
    Co-Investigator
  • Cancer Prevention and Research Institute of Texas (CPRIT), RP150416
    2015-2019
    Translational Investigations on Fenretinide and Safingol for Pediatric Cancer Use
    $1,900,000.00 [Total Cost]
    Co-Investigator
  • National Cancer Institute (NCI), R44 CA183316
    2014-2019
    A Phase I trial combining IV fenretinide and IV safingol to target overproduction of cytotoxic dihydroceramides in malignant cells.
    $522,606.00 [Total Cost]
    Co-Investigator
  • St Baldrick's Foundation
    2012-2018
    Pediatric Oncology Infrastructure Support
    $53,108.00 [Total Cost]
    Principal Investigator
  • Department of Defense, OC150083
    2016-2018
    Novel Platinum/Taxane-Based Drug Combinations (Preclinical) for Ovarian Cancer
    $378,322.00 [Total Cost]
    Principal Investigator
  • St Baldrick's Foundation
    2012-2015
    St Baldrick's NCCF - Support for Pediatric Trials; Principal Investigator
    $55,058.00 [Total Cost]

Selected Awards:

  • President's University Distinguished Professor Award, Texas Tech University Health Sciences Center, 2016.
  • Chancellor’s Council Distinguished Research Award, Texas Tech University Systems, 2011.
  • Covenant Health Systems David R. Close, MD Endowed Chair in Oncology , 2011.
  • Most Cited Paper, Clinical Cancer Research Journal (Issue 15:1126-1132), 2009.
  • Best Clinical Paper Award, Advances in Neuroblastoma Research Meeting, Chiba Japan, 2008.

Selected Scheduled Teaching:

  • Biology of Cancer - 2016
  • GCMB8000 Doctoral Dissertation - Spring 2014
  • GCMB6055 Laboratory Methods - Spring 2014
  • GCMB7000 Research - Spring 2014
  • MIDS5403 The Future of Medicine - TTUHSC Elective - Spring 2014

Selected Directed Student Learning:

  • Dissertation Committee Member 2010 - Present
  • Dissertation Committee Member 2016 - 2017

Selected Non-Credit Instruction Taught:

  • Grand Rounds - Cincinnati Children’s Hospital, Cincinnati, Ohio, Enhancing Activity of Anti-neoplastic drugs in pediatric oncology with novel drug formulations, April 2016
  • Educational Activities for the Lay Public - Littlefield Elementary School, Childhood Cancer, May 2015
  • Small Group Conferences - New Approaches to Neuroblastoma Therapy Consortium meeting Atlanta, Georgia, Update on LXS oral powder fenretinide phase 1 clinical trials, April 2015
  • Guest Lecture - UTHSC San Antonio Cancer Center, Improving the predictability for clinical activity of cell line and xenograft preclinical models for drug development in pediatric and adult cancers., March 2015
  • Grand Rounds - Baylor Hospital Dallas, TX, Dihydroceramides as a novel therapeutic target., February 2015
Research Interests

Cancer Developmental Therapeutics
Cancer Clinical Trials
Laboratory Models of Cancer
Retinoids
Alkylating Agents
Ewings Sarcoma
Neuroblastoma
Acute Lymphoblastic Leukemia
Lymphoma
Telomerase
Alternate Telomere Lengthening (ALT) Mechanisms in Cancer

I pioneered the development of the differentiating agent isotretinoin for treating the childhood cancer neuroblastoma, and developed clinical trials that established the world-wide standard of care for neuroblastoma. Together with Dr. Maurer we identified key mechanisms of action for cytotoxic retinoid fenretinide that have led to mechanistic-based drug combination clinical trials. We developed novel formulations that have enabled single agent fenretinide to achieve complete responses in early phase clinical trials of neuroblastoma and adult lymphomas.. I have established the largest collection of pediatric cancer cell lines and xenografts in the world and provide these laboratory models of childhood cancer freely to investigators in 20 different countries. A major focus of my lab currently is the study of telomere lengthening mechanisms as biomarkers and therapeutic targets for cancer.

Links

Date last updated: 10/14/2019